Epidemiological evidence demonstrates that metabolic dysfunction-associated steatotic liver disease (MASLD) has evolved into one of the most widespread chronic liver disorders globally, posing a serious public health challenge. From a mechanistic perspective, the initiation of MASLD is predominantly fueled by multiple factors. Multiple pathological processes, including insulin resistance, oxidative stress, and inflammatory response, are all closely associated with the core issue of mitochondrial